Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

RSV, the flu and coronavirus all soared in the U.S. and Europe this fall. There is no vaccine for adults currently on the market, but Moderna, Pfizer Inc. and GSK Plc. are each looking to be the ...

Moderna, Inc. (MRNA) announced late Thursday that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for adults aged 18-59 with underlying ...

Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s COVID-19 shots. The company said its vaccine is also being tested in an ongoing early stage trial in pediatric ...

Moderna’s vaccine for RSV gets FDA approval for people 60 and older By Jonathan Saltzman Globe Staff,Updated May 31, 2024, 7:14 p.m.

Moderna said it sees a corresponding operating profit from its Covid, RSV, and flu vaccines in the range of $4 billion to $9 billion in 2027.

BOSTON - Moderna claims its RSV vaccine is highly effective in older adults. The respiratory syncytial virus, which dominated respiratory infections just a few months ago, does not only cause ...

Moderna said its Phase 3 trial enrolled about 37,000 people ages 60 and older in 22 countries including the U.S. About half were given a single dose of the RSV vaccine and the other half received ...

Moderna said its Phase 3 trial enrolled about 37,000 people ages 60 and older in 22 countries including the U.S. About half were given a single dose of the RSV vaccine and the other half received ...